HopeStage
Back to all studies
CompletedNCT00521365

Quetiapine XR 600 mg for mania in bipolarity

About this title

Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.

Read the official source — NCT00521365

Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.

Medication studyAges 18–65Mexico
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Guadalajara and 6 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2008
Recruitment status
Completed
Enrollment listed in the registry
88
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Mexico
Age range
From 18 Years to 65 Years
Official registry ID
NCT00521365
Official title
Show the full official title

A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Guadalajara · Mexico City · Monterrey

4 more locations
  • San Pedro Garza García
  • San Luis Potosí City
  • Mérida
  • Durango

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine 600mg.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies